New hope to stop rare, aggressive skin cancer from coming back
NCT ID NCT03271372
Summary
This study is testing whether a drug called avelumab can help prevent Merkel cell carcinoma from returning in patients whose cancer had spread to lymph nodes. After completing standard surgery and/or radiation, 101 participants will receive either avelumab or a placebo via IV for up to two years. The goal is to see if this immunotherapy, which helps the immune system fight cancer, improves the time patients live without their cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III MERKEL CELL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of California Irvine Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
University of Colorado Cancer Center University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.